AstraZeneca’s proposed treatment for heart disease delivered positive high-level results from the company’s Phase III DELIVER trial.
When you have a brand with as much promise as Farxiga, you need someone at the helm with the drive and vision to help it reach its full potential. And that person is senior director of marketing for Farxiga, Allison Garrity. When Garrity joined the Farxiga team, the established AstraZeneca brand already had a strong legacy in type 2 diabetes (T2D), but momentum had stalled, teams needed to be rebuilt, and – the biggest challenge of all – Farxiga had to revolutionize care again, this time with indications in heart failure (HF) and chronic kidney disease (CKD).
The U.S. Food and Drug Administration (FDA) approved Bristol Myers Squibb’s oral heart disease drug, making Camzyos (mavacamten) the first cardiac myosin inhibitor to be permitted for use in the country.
The 71st annual American College of Cardiology’s Scientific Session saw several wins – and some “mehs” led by some of biopharma’s largest companies, according to BioSpace.
The U.S. health regulator approved Eli Lilly and partner Boehringer Ingelheim’s drug, Jardiance, for expanded use in reducing the risk of death and hospitalization for all patients with heart failure.
Biofourmis, a Boston-based global leader in virtual care and digital therapeutics, announced July 29 the company’s BiovitalsHF solution is the first-ever heart failure digital therapeutic to receive a Breakthrough Device designation from the U.S. Food and Drug Administration.
Sarfez Pharmaceuticals announced approval by the U.S. Food and Drug Administration of the Virginia-based company’s New Drug Application for Soaanz, a once-a-day improved formulation of the loop diuretic torsemide.
The U.S. Food and Drug Administration greenlit AstraZeneca’s Farxiga (dapagliflozin) under priority review for the treatment of chronic kidney disease in patients at risk of progression with or without type 2 diabetes.
Clarivate published the company’s annual “Drugs to Watch” list, and cited several medicines that the analysts expect to be blockbusters – projected to bring in $1 billion in sales annually.
Novartis’ Entresto is the first therapy approved in the United States to treat patients diagnosed with guideline-defined heart failure to include both those with heart failure with reduced ejection fraction (HFrEF) and many with heart failure with preserved ejection fraction (HFpEF).